(2S)-3-methyl-2-[[2-oxo-1-[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]hexyl]amino]butanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-3-methyl-2-[[2-oxo-1-[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]hexyl]amino]butanoic acid
• 化学式: C₂₄H₂₉N₅O₃
• 分子量: 435.5
• InChiKey: JHBGSMLHHGKNJX-HMTLIYDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] GPBP-1 INHIBITION AND ITS THERAPEUTIC USE<br/>[FR] INHIBITION DE GPBP-1 ET SON UTILISATION THÉRAPEUTIQUE
  申请人：FIBROSTATIN S L

  公开号：WO2014006020A1

  公开（公告）日：2014-01-09

  The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.

  本发明提供了包括抗肿瘤剂和Goodpasture抗原结合蛋白、p21和ABCC7的抑制剂的组合物，并将其用于治疗癌症。
• COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA
  申请人：S-Form Pharma

  公开号：EP4023218A1

  公开（公告）日：2022-07-06

  Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP > 200 pg/mL and/or has a level NT-proBNP > 600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40 %, preferably 50 %, or a patient with no heart failure.

  本发明的主题是一种用于治疗急性和/或持续性呼吸困难患者的复方药物，至少包含以下两种成分：血管紧张素转换酶（ACE）抑制剂、血管紧张素 II 抑制剂、血管紧张素 II 抑制剂或血管紧张素受体-肾素抑制剂（ARNi）和矿物质受体拮抗剂（MRA）的组合、格列酮类、环状作用利尿剂、其中，所述患者的体液样本的 BNP 水平大于 200 pg/mL，和/或 NT-proBNP 水平大于 600 pg/mL，且所述体液样本选自包括血液、血浆和血清的组，且所述患者为左室射血分数（LVEF）大于等于 40%（最好为 50%）的心衰患者或无心衰的患者。
• GPBP-1 INHIBITION AND ITS THERAPEUTIC USE
  申请人：Fibrostatin, S.L.

  公开号：EP2866835A1

  公开（公告）日：2015-05-06
• [EN] COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA<br/>[FR] POLYTHÉRAPIE POUR PATIENTS ATTEINTS DE DYSPNÉE AIGUË ET/OU PERSISTANTE
  申请人：[en]S-FORM PHARMA

  公开号：WO2022117893A2

  公开（公告）日：2022-06-09

  Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (AKNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP > 200 pg/mL and/or has a level NT-proBNP > 600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40 %, preferably 50 %, or a patient with no heart failure.